VolitionRx, an ambitious
life sciences company, wants to make non-invasive blood tests for cancer as
commonplace and easy to use as current blood tests for diabetes and high
cholesterol.
With only one blood test for
cancer—the Prostate-Specific Antigen test for prostate cancer—in common
clinical use, VolitionRx reasoned that existing cancer diagnostic tests were
inadequate. To address the unmet need in its field for accurate, inexpensive
cancer diagnostics with potential for economic growth, the company began
developing its NuQ brand of blood-based cancer diagnostic tests using its
proprietary Nucleosomics technology which measures and identifies nucleosome
structures in the blood. The presence of these structures in the bloodstream is
a warning that cancerous cells are also present.
VolitionRx is undergoing
clinical trials for its NuQ products. Once these clinical trials are complete
and regulatory approval is received, the company will offer blood tests for
individual cancers under the NuQ brand. The company currently sells its NuQ
immunoassays products to the research community and has plans to release a
range of simple blood tests that will continue to expand with both screening
and diagnostic cancer tests.
VolitionRx is also in the
midst of developing HyperGenomics, a new technology that aims to detect
specific signatures from cancer biopsies by reading hypersensitive sites along
the DNA string. These tests are being designed so that they can be used once
cancer has been diagnosed to correctly identify the specific subtype of the
disease and to help decide the most suitable therapy. Choosing the right
treatment approach can significantly improve the treatment outcome, reduce side
effects and deliver cost savings to paying patients.
VolitionRx’s research and
development activities are centered in Belgium at the time as the company is
focused on commercializing its diagnostic products first in Europe, then in the
US and ultimately, around the world.
For more information, visit
www.volitionrx.com
About MissionIR
MissionIR is committed to connecting the investment community with companies that have great potential and a strong dedication to building shareholder value. We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices.
Sign up for “The Mission Report” at www.MissionIR.com
MissionIR is committed to connecting the investment community with companies that have great potential and a strong dedication to building shareholder value. We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices.
Sign up for “The Mission Report” at www.MissionIR.com
Please see disclaimer on the MissionIR website http://www.missionir.com/disclaimer.html
